최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology, v.25 no.4, 2007년, pp.227 - 232
김수지 (가톨릭대학교 의과대학 방사선종양학교실) , 권은경 (서울대학교 의과대학 암연구소) , 이승희 (서울대학교 의과대학 암연구소) , 박혜진 (서울대학교 의과대학 암연구소) , 우홍균 (서울대학교 의과대학 암연구소)
Purpose: To investigate the flavopiridol effect on radiation-induced apoptosis and expression of apoptosisrelated genes of human laryngeal and lung cancer cells. Materials and Methods: A human laryngeal cancer cell line, AMC-HN3 and a human lung cancer cell line, NCI-H460, were used in the study. Th...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000;9:2903-2911
Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion Flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. J Clin Oncol 1998;16:2986-2999
Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19:1985-1992
Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of cyclin-dependent kinase inhibitor flavopiridol in patients previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001;7:1590-1599
Akilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003;14:1270-1273
Liu G, Gandara DR, Lara PN Jr, et al. A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004;10:924-928
Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-2170
Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-3845
El-Rayes BF, Gadgeels S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-310
Raju U, Nakata E, Mason KA, Kian Ang K, Milas L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003;63: 3263-3267
Jung C, Motwani M, Kortmansky J, et al. The cyclindependent kinase inhibitor flavopiridol potentiates $\gamma$ -irradiationinduced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003;9:6052-6061
Newcomb EW, Lymberis SC, Lukyanov Y, et al. Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle 2006;5: 93-99
Raju U, Ariga H, Koto M, et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 2006; 80:185-191
Kim SZ, Wu HG, Shin JH, Park HJ, Kim IA, Kim IH. Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells. Cancer Research and Treatment 2005;37: 191-195
Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004;71:213-221
Michalides RJ, van Veelen NM, Kristel PM, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997;123:497-502
Yoo SS, Carter D, Turner BC, et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000;90:22-28
Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001;96:159- 165
Alesssi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55- 62
Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267
Datta K, Bellacosa A, Chan TO, Tsichilis PN. Akt is a direct target of the phosphatidylinositol 3-kinase: activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem 1996;271:30835-30839
Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspases-9 by phosphorylation. Science 1998;282:1318-1321
※ AI-Helper는 부적절한 답변을 할 수 있습니다.